Patient teaching for a patient that is taking valproate should include (Select all that apply):

A. Insulin resistance: Valproate is not primarily associated with inducing insulin resistance. While metabolic changes can occur, insulin resistance is not a common or directly expected side effect to include in standard patient teaching. B. Amenorrhea: Valproate can disrupt hormonal balance in women, sometimes leading to menstrual irregularities, including amenorrhea. Patients should be informed about the potential for changes in their menstrual cycles. C. Polycystic ovaries: Valproate use has been associated with polycystic ovary syndrome (PCOS) in women, likely due to its effects on hormone regulation. Patient teaching should include awareness of this potential reproductive side effect. D. Weight loss: Valproate is more commonly associated with weight gain rather than weight loss. Counseling should focus on potential weight management rather than expecting weight reduction.